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Key Points
• Elevation of HbF in 3 patients
heterozygous for distinct
2p15-p16.1 syndrome
microdeletions affecting
BCL11A.
• Identification of novel,
putative regulatory elements
downstream of BCL11A that
govern its expression in
erythroid cells.
Elevated fetal hemoglobin (HbF) ameliorates the clinical severity of hemoglobinopathies
such as b-thalassemia and sickle cell anemia. Currently, the only curative approach
for individuals under chronic transfusion/chelation support therapy is allogeneic stem
cell transplantation. However, recent analyses of heritable variations in HbF levels have
provided a new therapeutic target for HbF reactivation: the transcriptional repressor
BCL11A. Erythroid-specific BCL11A abrogation is now actively being sought as a
therapeutic avenue, but the specific impact of such disruption in humans remains to be
determined. Although single nucleotide polymorphisms in BCL11A erythroid regula-
tory elements have been reported, coding mutations are scarcer. It is thus of great
interest that patients have recently been described with microdeletions encompass-
ing BCL11A. These patients display neurodevelopmental abnormalities, but whether
they show increased HbF has not been reported. We have examined the hematolog-
ical phenotype, HbF levels, and erythroid BCL11A expression in 3 such patients.
Haploinsufficiency of BCL11A induces only partial developmental g-globin silencing.
Of greater interest is that a patient with a downstream deletion exhibits reduced BCL11A expression and increased HbF. Novel
erythroid-specific regulatory elements in this region may be required for normal erythroid BCL11A expression, whereas loss of
separate elements in the developing brain may explain the neurological phenotype. (Blood. 2015;126(1):89-93)
Introduction
Chromosome 2p15-p16.1 microdeletions constitute a contiguous
gene deletion syndrome characterized by shared phenotypic traits
including intellectual disability, growth retardation, and distinct
dysmorphisms. To date, 11 microdeletions of discrete lengths have
been described, each associated with overlapping subsets of phe-
notypic features.1 These deletions collectively encompass approx-
imately 17 protein-coding genes and are accordingly associated
with a complex spectrum of physical andmental traits. The smallest
microdeletion yet has recently been reported to solely contain the
BCL11A gene and is associated with hypotonia, mild intellectual
delay, speech disorder, and gross motor impairments.1
BCL11A is a transcription factor that is highly expressed in the
brain, B-lymphocytes, and adult erythroid lineage. It has emerged
from several genome-wide association studies as a negative mod-
ulator of fetal hemoglobin expression.2-4 Indeed, BCL11A knockout
disrupts developmental silencing of human fetal g-globin in trans-
genic mice.5 Moreover, BCL11A knockdown in primary human
erythroid cells results in increased fetal hemoglobin (HbF),6whereas
conditional knockout in adult sickle cell disease transgenic mice
leads to reactivation of g-globin and amelioration of symptoms.7
Erythroid-speciﬁc abrogation of BCL11A has thus been pursued
as an attractive therapeutic for b-hemoglobinopathies.8 Although
HbF-associated single-nucleotide polymorphisms (SNPs) have
been shown to disrupt an erythroid enhancer in the second intron
of BCL11A, until recently, coding BCL11A mutations had not been
reported.9-11 Here we have investigated the hematopoietic param-
eters of 3 patients with distinct de novo, heterozygous deletions
encompassing, or proximal to, BCL11A. All display modestly re-
duced BCL11A expression and considerable HbF elevation. In
one patient, a downstream deletion that leaves the BCL11A coding
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gene intact results in reduced BCL11A transcripts in erythroblasts,
alluding to the existence of novel, erythroid regulatory elements
within this region.
Methods
See the supplemental Data, available on the BloodWeb site.
Results and discussion
The 3 patients herein have been described previously.12,13 The ﬁrst
is a 15-year-old female with a 3.5-Mb deletion downstream of
BCL11A (Figure 1A).13 The second and third are an 8-year-old
female and 7-year-old male with 642-kb and 2.5-Mb deletions,
respectively, covering the entire BCL11A gene (Figure 1A).12
Although their neurological and physical traits have been exten-
sively characterized, their hematopoietic proﬁles have not been pre-
viously assessed.
We ﬁrst determined the extent to which these heterozygous
deletions inﬂuence BCL11A expression in erythroblasts derived
from the 3 patients. In all cases,BCL11A transcripts were significantly
reduced by approximately twofold relative to parental expression
(Figure 1B). We also speciﬁcally analyzed the abundance of dif-
ferent BCL11A messenger RNA (mRNA) isoforms, and found
that those implicated in g-globin repression (BCL11A-XL and
BCL11A-L)5,6 were significantly downregulated in the patients’
erythroblasts, whereas short transcript variants (BCL11A-S) were
not (Figure 1B). Expression of KLF1 and GATA1, erythroid tran-
scription factors that regulate globin expression, was unaltered (data
not shown).
Complete blood counts revealed that hematological parameters
were largely normal in the 3 individuals (supplemental Table 1).
The third patient displayed mildly reduced hematocrit and in-
creased variability in red blood cell size at 5 months of age. These
ﬁndings were recapitulated in a follow-up count at 7 years of age.
This patient also exhibited modest lymphocytosis at this age.
BCL11A is highly expressed in B cells and has been implicated
in human B-lymphopoiesis.7,14 It should be noted, however, that
the ﬁrst 2 patients showed normal lymphocyte levels, suggesting
that these hypomorphic BCL11A mutations have minimal impact
on B-cell numbers.
We next assayed relative amounts of hemoglobin isoforms by
high-performance liquid chromatography (HPLC). All 3 patients
had markedly elevated fetal g-globin compared with their un-
affected parents (Figure 1C; supplemental Figure 1A). This was
reﬂected both as a fraction of total fetal plus adult b-like globin as
well as a-globin (supplemental Figure 1B,C). HPLC analysis of
hemoglobin tetramers determined the patients’ HbF levels to be
7.3%, 4.8%, and 6.2%, respectively, compared with that of their
parents (0.5%, 0.7% and 0.2%, and 0.2% and 0.6%) (Figure 1C).
Quantiﬁcation of individual globin chains revealed that fetalg-globin
represented 11.5%, 8.2%, and 10.0% of total b-like globin in the
3 patients compared with parental levels of 1.5%, 1.9% and 1.3%,
and 1.9% and 2.0% (supplemental Figure 1A). In all individuals,
a balanced ratio of b-like globin to a-globin was sustained (sup-
plemental Figure 1D).
These results demonstrate that BCL11A haploinsufﬁciency has
an appreciable effect on HbF expression. This mirrors ﬁndings of
the master erythroid regulator KLF1, an upstream activator of
BCL11A.15,16 In the short time since a nonsense mutation in KLF1
was initially linked to hereditary persistence of fetal hemoglobin,15
a raft of additional mutations in the locus have been described
resulting from focused sequencing efforts,17-20 culminating in the
recent discovery of a KLF1-null individual.21 Thus far, BCL11A
coding mutations have not been frequently encountered. Given its
implicated B-lymphopoietic and neurological roles, it is possible that
BCL11Amutationswith erythroid-restricted consequences (ie, elevated
HbF)will largely lie in regulatory elementswith erythroid activity (as in
Bauer et al9).
The approximately twofold downregulation of BCL11A mRNA
in patients 2 and 3 can likely be attributed tomonoalleleic expression
arising from BCL11A heterozygosity. However, in the ﬁrst patient,
both BCL11A alleles are intact (Figure 1A). This raises the possi-
bility that downstream regulatory elements within the deleted region
are required for full erythroid expression ofBCL11A. Inspection of this
region revealed several prominent DNase-hypersensitive sites in adult
erythroid cells that are cobound by various combinations of key
erythroid transcription factors (GATA1, TAL1, KLF1, and NFE2) and
are enriched for the active enhancer-associated marker H3K4me1
(Figure 2). These elements represent potential erythroid enhancers, al-
though their functional characterization remains to be determined. It is
also plausible that the deletion in patient 1 might result in reduced
BCL11A expression through alternative molecular mechanisms, such
as downstream heterochromatic regions being brought into the vicinity
of BCL11A.
The extent to whichBCL11Aneed be disrupted to induce clinically
protective HbF levels in sickle cell and thalassemic sufferers is un-
known. The patients here exhibit approximately 5% to 10% HbF and
twofold downregulated BCL11A mRNA. In sickle cell sufferers, such
HbF levels are associated with reduced major organ failure, but higher
amounts (.20%) are required to deter recurrent clinical crises.22 Fur-
ther, because of limited availability of tissue samples, we have been
unable to ascertain whether the increased HbF in these patients is
pancellular or heterocellular. This is an important consideration because
pancellular upregulation is predominantly associated with clinical
amelioration. Indeed, studies using transgenic, humanized sickle cell
mice found that HbF levels of approximately 10% or greater were clin-
ically beneﬁcial when expressed in at least two-thirds of peripheral
erythrocytes23 or higher.24
During the revision of thismanuscript, an additional 3 patients were
described, each with heterozygous 2p15-p16.1 deletions distinct from
those reported here. Each of these patients exhibited a similar reduction
in BCL11A expression to the cases here as well as persistence of fetal
hemoglobin and unperturbed lymphocytes. However, the reported
patients exhibited markedly higher levels of HbF (16.1-29.7%) than
those described here. The reason for this discrepancy is unclear, but
may be due to modiﬁers, genetic or otherwise, that inﬂuence ethnic or
regional variation in HbF levels.11
Last, it is worth noting that several of the genes deleted in the 3
patients are expressed during erythroid differentiation (Figure 1A), and
their deletion could thus conceivably contribute to the elevated HbF
observed. However, the striking phenotypic similarities of the patients
(in terms of both BCL11A and HbF levels) might suggest that the HbF
modiﬁer effects of these genes, which are variably deleted in different
combinations, are minimal.
Taken together, these ﬁndings suggest that modest downregu-
lation of erythroid BCL11A expression results in markedly in-
creasedHbF, supporting the utility of erythroid-speciﬁc disruption
of BCL11A as a therapeutic for b-hemoglobinopathies. That these
hypomorphic BCL11A mutations are associated with a spectrum
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Figure 1. Patients with 2p15-16.1 microdeletions display depleted BCL11A expression in erythroblasts and markedly increased fetal g-globin in peripheral blood.
(A) Schematic of the 2p15-16.1 region showing segments that are deleted in the 3 patients. In addition to BCL11A, the following deleted genes are expressed at 1 or more
stages during erythroid maturation:25 VRK2, FANCL, PAPOLG, REL, PUS10, PEX13, KIAA1841, C2orf74, AHSA2, USP34, XPO1, FAM161A, CCT4, COMMD1, and
B3GNT2. (B) Real-time reverse transcription-polymerase chain reaction quantification of BCL11A mRNA isoforms in erythroblasts expanded in vivo derived from patients
(n 5 3) and matched parents (n 5 5). Shown are total BCL11A transcripts, isoforms previously implicated in g-globin repression (BCL11A-XL and BCL11A-L) and short
variants (BCL11A-S). All levels have been normalized to GAPDH mRNA. Error bars represent standard deviation and P values signify analysis of variation comparison. (C)
HPLC determination of hemoglobin tetramer levels for the 3 patients and their parents. HbF peaks are shown in red. Note that HbA2 (a2d2) levels are relatively constant across
all samples (2.3%, 2.6%, and 1.6% for the patients, and 2.2%, 2.8% and 2.6%, 2.4% and 2.2%, respectively, for the parents).
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Figure 2. A downstream microdeletion associated with reduced BCL11A expression contains several putative erythroid enhancers. The region deleted in patient 1
is shown in red. Shown are DNase sequencing tracks for adult erythroblasts (derived from peripheral blood CD341 cells), other hematopoietic cells in which BCL11A is
expressed (B cells) or not expressed (T cells), and the developing fetal brain. Sequencing tracks have been emboldened for clarity. Potential erythroid regulatory elements are
highlighted with vertical bars and are bound in human pro-erythroblasts by different combinations of noted erythroid transcription factors (GATA1, TAL1, KLF1, and NFE2) as
evidenced by chromatin immunoprecipitation (ChIP) sequencing. These regions are also marked by H3K4me1, typically associated with active enhancer elements. Of note,
regions highlighted in pink display erythroid DNase hypersensitivity that is not present in the other hematopoietic cells, suggesting that they are erythroid-specific sites.
Regions in gray signify DNase-hypersensitive sites at an alternative VRK2 promoter and upstream element, which are present in other tissues. The segment in blue indicates
a known erythroid enhancer in BCL11A intron 2, to which SNPs associated with HbF levels are localized.9 A second cluster of high HbF-associated SNPs (marked by an
asterisk) lies downstream of BCL11A but outside the deleted region. The fetal brain exhibits widespread DNase hypersensitivity across the deleted region, which might
account for the neurological phenotype of this patient.
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of neurodevelopmental defects further emphasizes the need for
such abrogation to be erythroid-speciﬁc. We suggest that can-
didate erythroid regulatory elements, such as those described
previously9 and here, should be inspected during routine screen-
ing of HbF modiﬁers, and may represent targets for therapeutic
intervention.
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